作者
Richard J Auchus, Elizabeth O Buschur, Alice Y Chang, Gary D Hammer, Carole Ramm, David Madrigal, George Wang, Martha Gonzalez, Xu Steven Xu, Johan W Smit, James Jiao, Margaret K Yu
发表日期
2014/8/1
期刊
The Journal of Clinical Endocrinology & Metabolism
卷号
99
期号
8
页码范围
2763-2770
出版商
Oxford University Press
简介
Context
Chronic supraphysiological glucocorticoid therapy controls the androgen excess of 21-hydroxylase deficiency (21OHD) but contributes to the high prevalence of obesity, glucose intolerance, and reduced bone mass in these patients. Abiraterone acetate (AA) is a prodrug for abiraterone, a potent CYP17A1 inhibitor used to suppress androgens in the treatment of prostate cancer.
Objective
The objective of the study was to test the hypothesis that AA added to physiological hydrocortisone and 9α-fludrocortisone acetate corrects androgen excess in women with 21OHD without causing hypertension or hypokalemia.
Design
This was a phase 1 dose-escalation study.
Setting
The study was conducted at university clinical research centers.
Participants
We screened 14 women with classic 21OHD taking hydrocortisone …
学术搜索中的文章
RJ Auchus, EO Buschur, AY Chang, GD Hammer… - The Journal of Clinical Endocrinology & Metabolism, 2014